QCZ484 / Novartis, Argo Biopharma - LARVOL DELTA

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (ANZCTR) - P1 | N=68 | Completed | Sponsor: Novartis Pharmaceuticals Australia Pty Limited | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - P2 | N=380 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Dec 2027 ➔ Apr 2028

Trial completion date • Cardiovascular • Hypertension

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - P2 | N=380 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals

New P1 trial • Cardiovascular • Hypertension

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - P2 | N=380 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Cardiovascular • Hypertension